Unternehmen Coeptis Therapeutics, Inc. OTC Markets
Aktien
A3DK26
US19207C1045
COEP
Pharmazeutika
Kurzporträt
Mitarbeiterzahl: 6
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17.05.23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 30.08.23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 62 | 28.10.22 | |
Director/Board Member | 55 | 28.10.22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Gene Salkind
BRD | Director/Board Member | 71 | 28.10.22 |
Chris Calise
BRD | Director/Board Member | 51 | 28.10.22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Director/Board Member | 56 | 28.10.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 36 089 917 | 24 345 215 ( 67,46 %) | 0 | 67,46 % |
Unternehmenskontakt
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+34,00 % | 704 Mrd. | |
+29,29 % | 577 Mrd. | |
-7,75 % | 348 Mrd. | |
+18,53 % | 327 Mrd. | |
+4,95 % | 288 Mrd. | |
+13,79 % | 234 Mrd. | |
+4,93 % | 198 Mrd. | |
-9,78 % | 194 Mrd. | |
-4,89 % | 147 Mrd. |